Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study

  1. Orkin, C.
  2. Oka, S.
  3. Philibert, P.
  4. Brinson, C.
  5. Bassa, A.
  6. Gusev, D.
  7. Degen, O.
  8. García, J.G.
  9. Morell, E.B.
  10. Tan, D.H.S.
  11. D'Amico, R.
  12. Dorey, D.
  13. Griffith, S.
  14. Thiagarajah, S.
  15. St Clair, M.
  16. Van Solingen-Ristea, R.
  17. Crauwels, H.
  18. Ford, S.L.
  19. Patel, P.
  20. Chounta, V.
  21. Vanveggel, S.
  22. Cutrell, A.
  23. Van Eygen, V.
  24. Vandermeulen, K.
  25. Margolis, D.A.
  26. Smith, K.Y.
  27. Spreen, W.R.
  28. Erakutsi egile guztiak +
Aldizkaria:
The Lancet HIV

ISSN: 2352-3018

Argitalpen urtea: 2021

Alea: 8

Zenbakia: 4

Orrialdeak: e185-e196

Mota: Artikulua

DOI: 10.1016/S2352-3018(20)30340-4 GOOGLE SCHOLAR